Alkem Laboratories Limited (ALKEM.NS)
INR 5510.55
(0.32%)
INR 5510.55
(0.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 48.6 Billion INR | 12.47% |
| 2022 | 43.21 Billion INR | -17.24% |
| 2021 | 52.21 Billion INR | 31.82% |
| 2020 | 39.61 Billion INR | 8.99% |
| 2019 | 36.34 Billion INR | 37.86% |
| 2018 | 26.36 Billion INR | -1.64% |
| 2017 | 26.8 Billion INR | 35.02% |
| 2016 | 19.85 Billion INR | 7.92% |
| 2015 | 18.39 Billion INR | -16.81% |
| 2014 | 22.11 Billion INR | 53.32% |
| 2013 | 14.42 Billion INR | -13.87% |
| 2012 | 16.74 Billion INR | 31.13% |
| 2011 | 12.76 Billion INR | 11.46% |
| 2010 | 11.45 Billion INR | 223.59% |
| 2009 | 3.54 Billion INR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | -107.14 Billion INR | -320.44% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q2 | 47.01 Billion INR | 0.0% |
| 2023 FY | 48.6 Billion INR | 12.47% |
| 2023 Q4 | 48.6 Billion INR | 0.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 FY | 43.21 Billion INR | -17.24% |
| 2022 Q2 | 45.01 Billion INR | 0.0% |
| 2022 Q4 | 43.21 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q4 | 52.21 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 Q2 | 41.45 Billion INR | 0.0% |
| 2021 FY | 52.21 Billion INR | 31.82% |
| 2020 FY | 39.61 Billion INR | 8.99% |
| 2020 Q2 | 33.85 Billion INR | 0.0% |
| 2020 Q3 | - INR | -100.0% |
| 2020 Q4 | 39.61 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q2 | 31.38 Billion INR | 0.0% |
| 2019 FY | 36.34 Billion INR | 37.86% |
| 2019 Q4 | 36.34 Billion INR | 0.0% |
| 2018 FY | 26.36 Billion INR | -1.64% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 26.36 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q2 | 25.19 Billion INR | 0.0% |
| 2017 Q3 | - INR | -100.0% |
| 2017 FY | 26.8 Billion INR | 35.02% |
| 2017 Q4 | 26.8 Billion INR | 0.0% |
| 2017 Q2 | 24.88 Billion INR | 0.0% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q4 | 19.85 Billion INR | 0.0% |
| 2016 Q2 | 20.63 Billion INR | 0.0% |
| 2016 Q1 | - INR | -100.0% |
| 2016 FY | 19.85 Billion INR | 7.92% |
| 2016 Q3 | - INR | -100.0% |
| 2015 Q4 | 18.39 Billion INR | 0.0% |
| 2015 Q2 | 21.03 Billion INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 FY | 18.39 Billion INR | -16.81% |
| 2014 FY | 22.11 Billion INR | 53.32% |
| 2014 Q4 | 22.11 Billion INR | 0.0% |
| 2014 Q1 | - INR | 0.0% |
| 2013 FY | 14.42 Billion INR | -13.87% |
| 2012 FY | 16.74 Billion INR | 31.13% |
| 2011 FY | 12.76 Billion INR | 11.46% |
| 2010 FY | 11.45 Billion INR | 223.59% |
| 2009 FY | 3.54 Billion INR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Sigachi Industries Limited | 2.53 Billion INR | -1820.186% |
| Ind-Swift Limited | 13.45 Billion INR | -261.296% |
| Bajaj HealthCare Limited | 4.86 Billion INR | -898.527% |
| Sakar Healthcare Limited | 1.26 Billion INR | -3747.524% |
| Aurobindo Pharma Limited | 152.2 Billion INR | 68.067% |
| Innova Captab Limited | 4.89 Billion INR | -891.965% |
| Divi's Laboratories Limited | 18.99 Billion INR | -155.951% |
| AstraZeneca Pharma India Limited | 3.66 Billion INR | -1227.603% |
| Morepen Laboratories Limited | 4.45 Billion INR | -989.85% |
| Mankind Pharma Limited | 23.87 Billion INR | -103.584% |
| Sequent Scientific Limited | 8.27 Billion INR | -487.425% |
| Wanbury Limited | 3.15 Billion INR | -1440.318% |
| Laurus Labs Limited | 42.71 Billion INR | -13.79% |
| Nectar Lifesciences Limited | 11.21 Billion INR | -333.274% |
| Glenmark Life Sciences Limited | 5.18 Billion INR | -838.157% |
| Alembic Limited | 1.43 Billion INR | -3293.967% |
| Hikal Limited | 12.99 Billion INR | -274.031% |
| Alembic Pharmaceuticals Limited | 16.27 Billion INR | -198.67% |
| Neuland Laboratories Limited | 5.49 Billion INR | -783.958% |
| J. B. Chemicals & Pharmaceuticals Limited | 10.7 Billion INR | -353.913% |
| Glenmark Pharmaceuticals Limited | 65.11 Billion INR | 25.35% |
| IOL Chemicals and Pharmaceuticals Limited | 6.32 Billion INR | -667.985% |
| Themis Medicare Limited | 1.88 Billion INR | -2475.084% |
| RPG Life Sciences Limited | 1.38 Billion INR | -3421.591% |
| Zydus Lifesciences Limited | 71.79 Billion INR | 32.297% |
| Lupin Limited | 96.23 Billion INR | 49.495% |
| Amrutanjan Health Care Limited | 783.82 Million INR | -6101.009% |
| Wockhardt Limited | 39.87 Billion INR | -21.909% |
| Vaishali Pharma Limited | 371.16 Million INR | -12995.325% |
| Aarti Pharmalabs Limited | 8.25 Billion INR | -489.102% |
| Jagsonpal Pharmaceuticals Limited | 296.76 Million INR | -16278.555% |
| Jubilant Pharmova Limited | 61.27 Billion INR | 20.676% |
| FDC Limited | 3.7 Billion INR | -1210.388% |
| Dr. Reddy's Laboratories Limited | 106.96 Billion INR | 54.561% |
| Kilitch Drugs (India) Limited | 643.88 Million INR | -7448.732% |
| Eris Lifesciences Limited | 38.26 Billion INR | -27.012% |
| Venus Remedies Limited | 1.39 Billion INR | -3389.733% |
| ZIM Laboratories Limited | 2.08 Billion INR | -2235.923% |
| Bliss GVS Pharma Limited | 2.1 Billion INR | -2204.81% |
| Par Drugs and Chemicals Limited | 159.79 Million INR | -30317.858% |
| Caplin Point Laboratories Limited | 3.5 Billion INR | -1286.496% |
| Shilpa Medicare Limited | 12.93 Billion INR | -275.837% |
| Albert David Limited | 1.15 Billion INR | -4126.136% |
| Ajanta Pharma Limited | 10.71 Billion INR | -353.815% |
| Hester Biosciences Limited | 3.59 Billion INR | -1252.122% |
| Suven Pharmaceuticals Limited | 2.03 Billion INR | -2289.357% |
| Solara Active Pharma Sciences Limited | 14.09 Billion INR | -244.917% |
| Gufic Biosciences Limited | 5.59 Billion INR | -767.976% |
| Windlas Biotech Limited | 1.76 Billion INR | -2657.418% |
| Procter & Gamble Health Limited | 2.56 Billion INR | -1797.743% |
| Aarey Drugs & Pharmaceuticals Limited | 1.72 Billion INR | -2722.283% |
| Mangalam Drugs & Organics Limited | 1.97 Billion INR | -2359.38% |
| Granules India Limited | 22.95 Billion INR | -111.746% |
| Aarti Drugs Limited | 11.5 Billion INR | -322.505% |
| Bal Pharma Limited | 2.51 Billion INR | -1835.47% |
| Sun Pharmaceutical Industries Limited | 183.56 Billion INR | 73.522% |
| Lincoln Pharmaceuticals Limited | 1.07 Billion INR | -4423.31% |
| Medicamen Biotech Limited | 940.36 Million INR | -5068.727% |
| Unichem Laboratories Limited | 8.06 Billion INR | -502.348% |
| Bafna Pharmaceuticals Limited | 652.27 Million INR | -7351.566% |
| Biofil Chemicals and Pharmaceuticals Limited | 288.79 Million INR | -16730.044% |
| Valiant Laboratories Limited | 1.05 Billion INR | -4492.912% |
| Orchid Pharma Limited | 3.84 Billion INR | -1164.412% |
| Medico Remedies Limited | 438.24 Million INR | -10990.853% |
| Ind-Swift Laboratories Limited | 2.28 Billion INR | -2022.989% |
| Ipca Laboratories Limited | 33.74 Billion INR | -44.046% |
| Brooks Laboratories Limited | 248.6 Million INR | -19451.41% |
| Syncom Formulations (India) Limited | 1.16 Billion INR | -4071.348% |
| Piramal Enterprises Limited | 560.47 Billion INR | 91.328% |
| Torrent Pharmaceuticals Limited | 82.05 Billion INR | 40.762% |
| NATCO Pharma Limited | 10.53 Billion INR | -361.498% |
| Suven Life Sciences Limited | 148.62 Million INR | -32603.992% |
| Krebs Biochemicals & Industries Limited | 2.97 Billion INR | -1534.378% |
| Strides Pharma Science Limited | 37.68 Billion INR | -28.992% |
| Indoco Remedies Limited | 10.34 Billion INR | -369.963% |
| Alpa Laboratories Limited | 307.12 Million INR | -15725.958% |
| Lasa Supergenerics Limited | 541.92 Million INR | -8868.953% |
| Sun Pharma Advanced Research Company Limited | 3.89 Billion INR | -1148.555% |